Navigation Links
GeneTex Antibody Company to Launch a Line of New Zebrafish Primary Antibodies
Date:6/28/2011

IRVINE, Calif., June 28, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of high quality antibodies, is pleased to announce that they will be launching a full line of zebrafish antibodies.

Zebrafish have been increasingly utilized as a model organism for scientific research. Due to their short lifecycles and relatively large clutch sizes, they are a useful model for genetic studies. Zebrafish eggs are externally fertilized; therefore, researchers can control and manipulate the embryos from the moment of fertilization. In addition, their embryos are transparent, so researchers are able to observe the changes that occur throughout the developmental stages of the embryo.

"We believe the zebrafish is an excellent model organism for biological research," said Dr. Kristina Beiswenger, Product Specialist at GeneTex, "however, this field has long been overlooked and lacks quality antibody reagents. GeneTex is fully committed to developing high quality antibodies specifically validated with zebrafish samples. We will continue to expand this product line to satisfy the needs of zebrafish research."

Many zebrafish tissues and organ systems, including the kidney, pancreas, bones and heart, are comparable to those of higher mammals and humans. The relatively large size, large number and external development of zebrafish embryos make them especially agreeable to manipulation by a variety of chemical, physical and genetic methods.

GeneTex is launching one of the largest collections of zebrafish antibodies that are validated for western blotting, immunofluorescence (ICC/IF), immunohistochemistry (IHC) and other applications. Almost all of the antibodies in the line are antigen-affinity purified, which results in higher quality antibodies.

For additional information on GeneTex's full line of zebrafish antibodies, call toll-free 877-GENETEX (436-3839) or visit www.GeneTex.com/zebrafish.

About GeneTex:

GeneTex is an antibody company that was founded by scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex has over 35,000 primary antibodies in its catalog that are all backed by a 100% Satisfaction Guarantee.  


'/>"/>
SOURCE GeneTex
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
4. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
5. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
6. SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification.
7. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
8. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
9. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
10. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
11. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... City, Missouri (PRWEB) , ... May 27, 2016 , ... ... Development Manager, Turf and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave ... Herbicide Product Manager, where he was integral in the development and launch of many ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... state, but investors playing in this space know that volatility ... this morning,s featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... CTIC ), Lpath Inc. (NASDAQ: LPTN ), and ... now and gain access to the technical alerts for these ...
(Date:5/26/2016)... , May 26, 2016 Q BioMed ... it will be a featured presenter at the 5th Annual ... New York City at the Grand Hyatt ... , Q BioMed Inc. CEO, is scheduled to begin at ... the company,s business strategy, recent developments and outline milestones for ...
(Date:5/26/2016)... ... 26, 2016 , ... Kinder Scientific (KinderScientific.com), a leading animal ... the Company for the future. Kinder Scientific announces restructured ownership and additional ... appointed Chairman of the Board, Curtis D. Kinghorn has been appointed CEO/President and ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):